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ABSTRACT

Complete and using the search terms Ebola,

In 2014 and 2015, the largest Ebola virus

Ebola virus disease, Ebola hemorrhagic fever,
West Africa outbreak, Ebola transmission,

disease (EVD) outbreak in history affected

Ebola symptoms and signs, Ebola diagnosis,

large populations across West Africa. The
goal of this report is to provide an update

Ebola treatment, vaccines for Ebola and
clinical trials on Ebola. Through 22 July

on the epidemic and review current progress
in
the
development,
evaluation
and

2015, a total of 27,741 EVD cases and 11,284
deaths were reported from all affected

deployment

countries.

of

prevention

and

treatment

Several

therapeutic

agents

and

strategies for EVD. Relevant information was
identified through a comprehensive literature

novel vaccines for EVD have been developed
and
are
now
undergoing
evaluation.

search using Medline, PubMed and CINAHL

Concurrent with active case investigation,
contact tracing, surveillance and supportive

Electronic supplementary material The online
version of this article (doi:10.1007/s40121-015-0079-5)
contains supplementary material, which is available to
authorized users.

care to patients and communities, there has
been rapid progress in the development of
new therapies and vaccines against EVD.
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and public health infrastructure will have
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deployment of new drugs and vaccines to
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direct benefits in controlling the spread of

affected
countries
when
they
become
available. The unprecedented West Africa
Ebola

outbreak,

response

measures,

and

ensuing drug and vaccine development
suggest that new tools for Ebola control may
be available in the near future.

Infect Dis Ther (2015) 4:365–390

366

Keywords: Africa;

Anti-viral;

EBOV;

EVD;

Hemorrhagic fever; Immunization; Treatment;
Vaccine

Ebola virus (EBOV) derived its name from the
Ebola River in Democratic Republic of Congo
(DRC) (formerly Zaire) where the first Ebola
virus disease (EVD) outbreak was identified in
1976 [1]. Historically, outbreaks of EVD have
been confined to a single country and have
been brought under control by domestic health
agencies working in conjunction with
international organizations such as the World
Health Organization (WHO). However, since
March 2014, West African countries, notably
Guinea, Liberia and Sierra Leon, have
experienced the largest EVD outbreak in their
history [2]. Although the origins of EVD in the
most
recent
outbreak
remain
under
investigation, the spread of EBOV occurred
rapidly because of a number of factors
including funeral and burial practices for
decedents [3, 4].
The scope and severity of the EVD outbreak
underscore the urgent need for development
and evaluation of affordable therapeutic and
prophylactic agents that can be made available
for at-risk populations across Africa. Over the
past 17 months, the West Africa EVD outbreak
has provided an important opportunity to
consider use of and evaluate several
and

prophylactic

We

reviewed

reports

from

peer-reviewed literature published from 1993
through 2015 and cited in several electronic
databases including Medline, PubMed and
CINAHL Complete on ‘‘Ebola,’’ ‘‘Ebola virus
disease,’’ ‘‘Ebola hemorrhagic fever,’’ ‘‘West

INTRODUCTION

therapeutic

EVD.

agents

(e.g.,

vaccines) to determine their safety and efficacy
[5, 6].
Review Methods

Africa outbreak,’’ ‘‘Ebola transmission,’’ ‘‘Ebola
symptoms and signs,’’ ‘‘Ebola diagnosis,’’
‘‘Ebola treatment,’’ ‘‘vaccines for Ebola’’ and
‘‘clinical trials on Ebola’’ (Fig. 1). The gray
literature, health organization websites,
clinical trial registries and corporate websites
were inspected and reviewed to identify
up-to-date information relevant to Ebola.
Studies were included in the proposed
literature review if they (1) were published
in the English language; (2) were full-text
articles; (3) focused on Ebola virus virology,
epidemiology, diagnosis, treatment and
clinical trials on vaccines and treatment; (4)
were published between 1993 and 2015; (5)
were published in peer-reviewed journals. We
excluded studies if they (1) were not full-text
articles; (2) were published before 1993; (3)
were
published
in
non-peer-reviewed
journals. We identified 156 studies for
inclusion in this review. Seventy-one studies
focused on epidemiology, public health
issues,

unpublished reports related to EBOV and

syndrome

of

EVD

and

diagnostic tools. An additional 89 studies
provided information on therapeutic and
vaccine clinical trials that target EBOV. Data
were
abstracted
from
published
and
unpublished

reports

to

describe

disease

patterns, burden of illness in past and
present outbreaks as well as effects of
investigational therapies and vaccines. This
article is based on previously conducted
studies

For this review, we considered published and

clinical

and

does

not

involve

studies of human or animal
performed by any of the authors.

any

new

subjects
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Fig. 1 Flowchart for the literature search
Virology

and Bundibugyo ebolavirus). In contrast, the
genus Marburgvirus contains a single virus

Filoviruses (family Filoviridae) are enveloped,
linear,
non-segmented,
negative
and

species

single-stranded RNA viruses belonging to the
order
Mononegavirales.
Ebolavirus
and
Marburgvirus are the two genera of filoviruses
that have been identified to cause severe
disease in humans [7, 8]. Within the genus
Ebolavirus, five viruses are recognized (EBOV,
Sudan virus, Reston virus, Taı̈ Forest virus and
Bundibugyo virus) with each representing a
different virus species (Zaire ebolavirus, Sudan
ebolavirus, Reston ebolavirus, Taı̈ Forest ebolavirus

(Marburg

marburgvirus),

and

two

distinct viruses have been recognized,
Marburg virus and Ravn virus [9–11]. In 2011,
a novel third genus of filovirus named
Cuevavirus was reported from post-mortem
tissues of bats collected in 2002 in Northern
Spain [12]. Cuevavirus has not been grown in
cell culture, and its pathogenic potential for
humans remains unknown. To date, a single
species (Lloviu cuevavirus) has been approved by
the International Committee on Taxonomy of
Viruses (ICTV) [9].

Infect Dis Ther (2015) 4:365–390
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The current West Africa outbreak is caused

remained stable during the current Ebola

by Zaire ebolavirus, which shows 97% identity to

outbreak [23].

EBOV strains from the DRC and Gabon [13].
The genome of EBOV contains seven genes

Epidemiology and Outbreaks

named nucleoprotein (NP), virion protein (VP)
24, VP30, VP35, VP40, glycoprotein (GP) and L

Ebola viruses have been responsible for 33

protein [14]. Each one of these genes encodes a
corresponding structural protein. The main
proteins targeted by experimental treatments

outbreaks in six African
Historically, the outbreaks
hundreds

of

individuals

countries [2].
have affected
where

effective

are the NP, VP35, GP, VP24 and L protein. NP is
the main component of the viral nucleocapsid

control of outbreaks was achieved primarily
through isolation of cases and contact tracing.

and encapsulates the viral RNA. VP35 is also

However, from 2000, EVD outbreaks have been
recognized almost every year with substantial

part of the nucleocapsid and, together with
VP24, interferes with innate host immunity.

variation in morbidity and case-fatality rates

The surface GP is responsible for the attachment
to the cellular receptor and viral entry. L protein

ranging from 24% to 81% [24]. High
case-fatality rates have been associated with

is the RNA-dependent RNA polymerase [15–20].

the Zaire and Sudan subtypes [25]. In the
ongoing
Ebola
outbreak,
the
overall

Early reports suggest that the EBOV variant
of the 2014–2015 West Africa outbreak

case-fatality rate has been estimated to be

accumulated mutations that may have an
impact on the performance of certain

approximately 41% for West Africa and other
affected countries [26]. Most recently, although

diagnostic tests or even on the efficacy of
several experimental treatments. Gire et al.

the number of cases has declined substantially
(Fig. 2), EVD cases continue to be reported

analyzed the genetic sequence of 99 EBOV

(please see the supplemental table for details)
in Guinea, Liberia and Sierra Leone with WHO

genomes from 78 patients in the four most
affected countries of the West African region

Ebola situation reports noting weekly cases in

[16]. They found significant rates of genomic
variation in EBOV in the current outbreak when

July 2015 [27]. In July 2015, situation report
statistics from the WHO suggest that the

compared with the EBOV genomic sequence in

greatest current burden of EVD is found in
Guinea (n = 43) and Sierra Leone (n = 31).

the 2004 Ebola outbreak in the DRC. Although
the impact of these mutations on the diagnostic

Liberia reported the lowest EVD case number

tests and experimental therapeutics has not yet
been proven, some mutations exist in viral

(n = 3) in the week of 29 June through 5 July
[27].

genes that are targeted by primers of some

The search for the natural reservoir host of
EBOV has been a matter of investigation during

reverse transcription-polymerase chain reaction
(RT-PCR) protocols [21], as well as mutations in

the last decades. There is mounting evidence

the binding sites of target proteins of some
experimental treatments such as anti-GP

that a number of mammal species may harbor
and transmit the virus. Several bat species (i.e.,

monoclonal antibodies [22]. In 2015, Hoenen

Epomops franqueti, Hypsignathus monstrosus and
Myonycteris torquata) have been found to carry

and colleagues studied full-length sequences of
two clusters of EBOV imported from Mali and
found that the gene sequence of EBOV has

filoviruses [28–35]. In addition, EBOV viral RNA
and/or antibodies have been found in these

Infect Dis Ther (2015) 4:365–390
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Fig. 2 Map of the West African region showing the
number of days passed since the last case reported to the
World Health Organization. Last updated 24 June 2015.
Reprinted from the Ebola Response Roadmap. Map of

West Africa showing when the last cases of Ebola occurred.
24 June 2015. http://www.cdc.gov/vhf/ebola/outbreaks/
2014-west-africa/distribution-map.html. Copyright 2015

animals [30, 32, 34], and Marburg virus has
been isolated from Egyptian fruit bats (Rousettus

Nevertheless, the EBOV viral load by organ has
not been extensively studied although EBOV

aegyptiacus) [29].

has been detected in the semen of survivors up

TRANSMISSION AND CLINICAL
SYNDROME

to 3 months following onset of symptoms [41,
42]. EBOV has been isolated from urine and
from aqueous humor samples 9 days and
9 weeks, respectively, after the virus was

Humans may acquire the disease by close

cleared from plasma [37, 43].

contact with biological fluids from infected

The clinical presentation of the current West
Africa outbreak is, in general, similar to that

animals or patients. During the acute phase of
illness, EBOV has been detected in a variety of
body fluids including breast milk, saliva, semen,
stool, sweat, tears and urine [36–40].

described in prior
incubation
period

EBOV epidemics. The
for
person-to-person

transmitted EVD typically ranges from 8 to

Infect Dis Ther (2015) 4:365–390
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11 days, but cases have been reported with

patients less than 10 years of age and others

incubation periods as short as 2 and as long as

between 11 to 20 years old, but they found that

21 days. Shorter incubation periods may be
observed following direct inoculation of virus

patients aged \30 years had a much lower case
fatality rate than those aged [30 years [22/38

through injection with contaminated needles
[44, 45]. Patients often present to health care

(57.9%) and 20/23 (87.0%), respectively, with
p = 0.0175] and that survivors attended Ebola

providers within 1 week of symptom onset [21,

Treatment Centers earlier after the onset of

46]. In the early clinical phase of EVD, patients
manifest signs and symptoms that mimic

symptoms [53]. No evidence suggests that
pregnant women are more susceptible to

common tropical illnesses (e.g., dengue,
malaria, typhoid fever and other viral

EBOV infection than the general population.
However, they might be at increased risk of

infections) [16, 47, 48]. The onset of the

severe illness and fetal loss. Although no large

disease includes nonspecific clinical signs such
as fever, headache, extreme asthenia, arthralgia,

series are available, the fetal outcome is
generally fatal.

myalgia
and
back
pain.
Progressive
gastrointestinal (GI) symptoms often develop

Immune suppression and a systemic
inflammatory response due to the release of

within 3 to 5 days of symptom onset [44,

cytokines and other proinflammatory mediators

49–51]. GI manifestations include abdominal
pain, anorexia, nausea, vomiting and diarrhea,

lead to the impairment of vascular, coagulation
and immune systems [54]. This can result in

which lead to profound electrolyte imbalance,
intravascular volume depletion and shock.

multiorgan failure and shock resembling a
septic shock syndrome. Massive fluid losses

Conjunctival
injection,
rash,
hiccups,
respiratory and neurologic findings have been

due to intense vomiting and profuse diarrhea
can result in dehydration and hypovolemic

also reported. Bleeding is a late clinical sign that

shock [49]. Severe lymphopenia as well as

occurs only in less than 20% of patients with
EVD [44]. However, if hemorrhage occurrs, a

significant deterioration of renal and liver
functions, which may be reflected in high

dismal outcome can be predicted. In 2015, Barry
et al. studied the correlation between the

blood urea nitrogen, serum creatinine and
hepatic enzymes (i.e., aminotransferases and

occurrence of symptoms and death in 89

alkaline phosphatase), can occur [21, 55, 56].

patients with EVD. These investigators found
hemorrhage, shortness of breath and myalgia

Since EBOV is a contagious pathogen, the
WHO and Centers for Disease Control (CDC)

were independently associated with death [52].
Clinical deterioration may progress rapidly

have issued recommendations for proper
handling of biological specimens from

resulting in death within 7 to 10 days.

suspected cases of EVD [57, 58]. Extreme

Vulnerable populations include children
under the age of 5 years, pregnant women and

caution should take place at all stages (i.e.,
specimen acquisition, transport, processing and

the elderly [49]. EVD in these groups also
include unspecific symptoms in the clinical

testing)
of
specimen
processing,
and
appropriate biosafety laboratory procedures

presentation.

must

differences

Qin
related

et
to

al.

did

mortality

not

find

between

be

used

when

handling

biological

specimens from patients with suspected EVD.
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DIAGNOSIS OF EBOLA VIRUS
DISEASE

onset of symptoms with a peak of IgM levels
occurring in the 2nd week of illness [41, 48, 62].

Rapid and reliable diagnosis of EVD is essential
for
appropriate
and
effective
patient
management,

hospital

or

health

center

infection prevention and control, and
optimization of use of healthcare resources
[59]. Diagnosis of suspected cases is confirmed
by EBOV-specific laboratory tests that detect the
EBOV genome (e.g., RT-PCR) or measurement of
the EBOV antigen or specific antibodies [42]. In
the past 10 months, the West Africa EVD
outbreak has stimulated the development of
new diagnostic tests, including rapid antigen

IgM antibodies are cleared at variable rates from
1 to 6 months after illness onset [41]. Data
showed that serology can be highly specific for
the EVD diagnosis but less sensitive in the
intensive care unit setting. Hence, antibody
testing may be less clinically useful in the
diagnosis and management of critically ill EVD
patients [49]. Although IgG antibodies appear
soon after the IgM and may persist for years
[41], a substantial number of EVD patients have
died before they develop an IgG antibody
response [48].

detection tests and nucleic acid detection (NAT)

Reverse Transcription Polymerase Chain

tests such as loop-mediated isothermal
amplification (LAMP) assays [60, 61].

Reaction (RT-PCR)
Nucleic acid tests (NATs), particularly RT-PCR,

Enzyme-Linked Immunosorbent Assay

are regarded as the gold standard for EVD
diagnosis, in part because of their high

Antigen Detection
Prior to 2000, antigen detection methods [e.g.,

sensitivity and specificity in detecting the
Ebola viral genome. This is generally

enzyme-linked immunosorbent assay (ELISA)]
were the gold standard for EBOV detection in

accomplished by international mobile teams
deployed in institutions such as the European

some outbreaks [62]. In the acute phase of EVD,
ELISA has a relatively high sensitivity (93%), but

Mobile Laboratory or CDC. RT-PCR is a rapid

disease

and highly sensitive nucleic acid amplification
test to detect EBOV nucleic acid [65]. The

progresses, rendering lower sensitivity for
antigen
detection
1–2 weeks
following

sensitivity and specificity of RT-PCR are
approximately 100% and 97%, respectively

EBOV

antigen

levels

decline

as

symptom onset [41, 63]. Several other antigen
detections tests are currently under evaluation

[63].

Within

the

first

3 days

of

illness,

and may be deployed in the near future to

molecular assays may not detect the viral
genome, which may lead to false-negative

complement RT-PCR testing [60]. ELISA testing
has been largely replaced by RT-PCR, which

results. Therefore, RT-PCR should be repeated
in subsequent samples [49, 66]. To minimize

permits more rapid detection and can now be
deployed in mobile (portable) testing platforms

false-negative

results,

proper

sampling,

in outbreak settings [64].

collection, storage or transportation, and a
proper RT-PCR technique have to be

Antibody Detection

implemented to avoid cross-contamination
[49, 54]. Quantitative RT-PCR has been

Detection of IgM antibodies against EBOV is
performed by ELISA in the first week after the

developed and could possibly be used to
monitor the viral load since data suggest high

Infect Dis Ther (2015) 4:365–390
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viremia might be associated with unfavorable

information. However, once an Ebola outbreak

outcomes and death [21, 46]. For those patients

is suspected, faster methods such as specific

receiving experimental treatments, EBOV viral
load monitoring could be useful to assess

real-time RT-PCR protocols are preferred for
screening of suspected patients. In this setting,

treatment response [48].
The WHO recommends that specimens

NGS techniques are valuable tools for
full-length genomic analysis, identification of

tested by RT-PCR outside of the designated

viral

EBOV diagnostic laboratories should be sent to
a WHO Collaborating Center for confirmatory

emerging viral mutations.
The development of rapid point-of-care

testing. These collaborating centers include the
Institut Pasteur de Lyon (France) and the

diagnostic tests has accelerated in the face of
the West Africa outbreak. These tests may

Bernhard-Nocht

variants

and

detection

of

possible

Tropical

provide viable options for Ebola diagnosis

Medicine (Germany), National Microbiology
Laboratory Public Health Agency of Canada

particularly in field settings. The results of
rapid Ebola test evaluations suggest that assays

(Canada), Centre International de Recherches
Médicales de Franceville (Gabon), Kenya

have reached high sensitivity (100%) and
specificity (90%) [69–71]. Although rapid

Medical Research Institute (Kenya), Institut

diagnostic tests are promising tools, they are

Pasteur de Dakar (Senegal), National Institute
for Communicable Diseases (South Africa),

not yet used in daily practice, and real-time
RT-PCR remains the gold standard for EVD

Uganda Virus Research Institute (Uganda) and
the Centers for Disease Control and Prevention

diagnosis.

(USA) [58].
Portable PCR techniques are currently under

THERAPY

development

Supportive Care

and

Institute

featured

for

to

be

readily

deployed in the field for rapid diagnosis
(10–30 min). These techniques are anticipated
to have minimum biosafety requirements and
do not require laboratory infrastructure [67].

The provision of clinical supportive care is now
a cornerstone of EVD patient management,

Portable PCR techniques can play a more

which
includes
rehydration,
nutrition,
analgesics and blood transfusion when

effective role in disease surveillance and
control including Ebola outbreaks and other

appropriate, though no clear evidence proves
their effectiveness [21]. A key aspect of

infectious diseases [68].

supportive

Other Diagnostic Approaches

intravascular volume with oral rehydration
solution (ORS) or intravenous fluids that

Next-generation sequencing (NGS) techniques

provide appropriate electrolyte replacement.
The use of antiemetics and antidiarrheal

provide powerful methods that allow screening
for a wide number of pathogens and provide
complete genome data. NGS methods may be
useful to detect Ebola virus in situations where

care

is

the

maintenance

of

agents may also be important for patients with
persistent vomiting and diarrhea [21, 49, 50].
Prophylactic
antimicrobial
agents
with

the clinical index of suspicion is not high or

intravenous third-generation cephalosporins
(e.g., ceftriaxone and cefotaxime) may be

where there is low urgency for diagnostic

administered

when

secondary

bacterial
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infections and septicemia are suspected [72].

EVD in Europe and the US with most of them

Parasitic coinfections (e.g., malaria) can occur,

surviving the disease, but because these patients

and appropriate diagnosis and treatment for
these diseases are recommended whenever

received other experimental therapies including
hyperimmunoglobulin serum and proper

feasible [73].

supportive care in medically advanced
facilities, clear evidence of effectiveness and

Targeted Antivirals Compounds/Drugs

safety in humans is lacking [76]. In 2014,

The high case-fatality rate associated with

TKM-Ebola entered phase I clinical trials to
evaluate the safety and pharmacokinetics

advanced EVD highlights the need for
therapeutic agents that reduce, inhibit or

among
clinical

eliminate EBOV from infected tissues and
organs. An available effective treatment would

mediator (cytokine) appeared in participants

volunteer participants. However,
manifestations
of
inflammatory

be necessary for outbreak management in order

who were treated with TKM-Ebola [77, 78].
Given the observed adverse events, the US

to improve the prognosis of infected patients as
well as to reduce the viral load and therefore the

Food and Drug Administration (FDA) placed a
partial clinical hold on the trial. Since dose

risk of new infections. Among experimental
antiviral
treatments,
several
potential

modifications

were

introduced

in

the

promise

TKM-Ebola trial, the FDA has allowed
continuation of the study for patients with

(Table 1), and their mechanisms of action are
different [6].

EVD. Currently, one TKM-Ebola phase I trial is
active and being undertaken in San Antonio,

Small Interfering RNA Agents

Texas, and another TKM-Ebola phase I trial has
been terminated by Tekmira, Inc., aiming to

therapeutic

agents

have

shown

One formulation (i.e., TKM-Ebola) of small
interfering RNAs (siRNAs) that target EBOV is

reformulate

the

investigational

therapeutic

encapsulated in lipid nanoparticles to facilitate

(Table 1). Additionally, Tekmira, Inc., started a
phase II trial on TKM-Ebola in Guinea.

cellular delivery. SiRNAs cause cleavage in the
messenger RNAs, which subsequently prevent

However, on 19 June 2015, Tekmira, Inc.,
released a letter stating that the phase II trial

EBOV production of three key viral proteins.
Early animal studies have demonstrated that

closed

enrollment

prior

to

completion.

animals

Preliminary data from the incomplete phase II
trial indicated no therapeutic benefit was

challenged with a lethal dose of EBOV [74,
75].
TKM-Ebola
was
administered
by

achieved from the use of TKM-Ebola. A full
report from this trial is pending [79].

TKM-Ebola

prevents

infection

in

intramuscular injection to two groups of
macaques 30 min following receipt of a lethal

Other

siRNA-based

agents

are

in

dose of EBOV. One group was treated with

development, including phosphorodiamidate
morpholino oligomers [80–82]. These agents

TKM-Ebola on days 1, 3 and 5 post-exposure,
and the other group was treated post-exposure

include AVI-6002 and AVI-6003, which are
composed of multiple oligomers with

every day for 6 consecutive days. The first
regimen provided 66% protection, and the

positively charged piperazine residues located

second gave 100% protection [74]. Although
the drug was tested on quite a few patients with

along the oligomeric backbone. In 2011, a
phase
I
randomized,
double-blind,
placebo-controlled, single-dose, dose-escalation

Infect Dis Ther (2015) 4:365–390
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Table 1 Overview of Ebola virus therapeutics in development
Agent

Manufacturer

Stage of evaluation

ClinicalTrials.gov
identiﬁer number

TKM-Ebola [74]

Tekmira (Burnaby, British Columbia,
Canada)

Phase I ongoing

NCT02041715

Phase I terminated

NCT01518881

T-705 (Favipiravir)
[93, 150, 151]

Institut National de la Santé Et de la
Recherche Médicale, France

Phase II ongoing

NCT02329054

CMX001
(Brincidofovir)
[98]

Chimerix (Durham, NC)

Phase II (withdrawn prior
recruitment)

NCT02271347

JK-05 [152]

Sihuan Pharmaceutical

BCX4430 [95]

BioCryst Pharmaceuticals
Inc., Durham, NC

Phase I ongoing

NCT02319772

AVI-6002 [80, 82]

Sarepta Therapeutics (Cambridge, MA)

Phase I completed

NCT01353027

Anti-Ebola
hyperimmune
globulin [140,
153, 154]

None identiﬁed

Animal studies completed

N/A

ZMapp [132, 135,
155, 156]

Phase I/II ongoing
National Institutes of Health Clinical
Center (National Institute of Allergy and
Infectious Diseases (NIAID)

Animal studies completed; now N/A
considered for use in emergency
Holdings Group Ltd and Academy of
Military Medical Sciences (Beijing, China) situations for army only

NCT02363322

FDA US Food and Drug Administration, N/A not applicable
trial to assess the safety, tolerability and

positive-strand RNA viruses [83–88]. Initially,

pharmacokinetics of AVI-6002 in healthy adult
subjects was completed (ClinicalTrials.gov

favipiravir was developed to treat influenza
viruses, and a phase III clinical trial was

Identifier: NCT01353027). In a similar trial,

completed in which favipiravir was tested on

the same group of investigators evaluated the
use of AVI-6003 against Marburg virus as a

several thousands of people and proven to be
safe and effective [84]. Recently, favipiravir has

post-exposure
therapy
(ClinicalTrials.gov
Identifier: NCT01353040). In these trials, both

also shown efficacy against EBOV in vitro and
in vivo in a mouse model [89]. Two

AVI-6002 and AVI-6003 were well tolerated by

independent

healthy human volunteers [80].

demonstrated that treatment with favipiravir
resulted in rapid viral clearance and led to

Favipiravir (T-705)
Favipirarvir is a nucleotide analog and viral RNA

survival of all animals infected with EBOV
through intranasal inoculation [89, 90]. A

polymerase inhibitor with a wide range of
antiviral effects against numerous negative- or

phase II clinical trial to evaluate the efficacy of

animal

studies

have

favipiravir against EBOV in 225 patients with an

Infect Dis Ther (2015) 4:365–390
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EVD trial has been completed in Guinea [91,

prevents viral replication by inhibiting DNA

92]. The investigators of this trial are in the

polymerase

midst of data analysis with results forthcoming
in the near future. The French drug safety

broad- spectrum antiviral activity against DNA
viruses such as herpes viruses and adenovirus

agency approved compassionate use of
favipiravir in patients with EVD [93], and the

and is currently in a phase III clinical trial
against cytomegalovirus and adenovirus [98,

drug was used to treat a French nurse who

99]. Although the exact mechanism of action

contracted EBOV while a volunteer with
Médecins Sans Frontières (MSF) in Liberia [94].

for brincidofovir in EVD is not yet well
understood, brincidofovir may interfere with

BCX4430

RNA polymerase of EBOV. The US FDA has put
brincidofovir on fast-track approval for

BCX4430 is a novel adenosine analog that
inhibits viral RNA polymerase activity, which

[97].

Brincidofovir

has

shown

treatment of EVD based on in vitro data alone

results in termination of RNA synthesis. This

[99]. A phase II open-label multicenter study to
assess the safety and efficacy of brincidofovir

compound has shown promising results and
confers protection to EBOV-challenged mice

against EBOV in humans has been withdrawn
prior recruitment (ClinicalTrials.gov Identifier:

and monkeys, even when administered
following challenge with filoviruses such as

NCT02271347). As a result of the dramatic

Marburg and Ravn viruses [95]. Furthermore,

decline in the number of new cases in Liberia
in the month of January 2015 where the trial

BCX4430 has demonstrated broad-spectrum
antiviral activity against many viruses,

was first initiated, Chimerix, Inc., decided to
discontinue the trial with no further discussions

including
bunyaviruses,
arenaviruses,
paramyxoviruses,
coronaviruses
and

[100].

flaviviruses [95]. From a safety perspective, it is

Other Small Molecules and Compounds

worth noting that BCX4430 may have an
acceptable side effect profile as it does not

There are a number of known agents and newly
identified compounds that have shown

incorporate into human RNA or DNA. In vitro
activity against EBOV has been shown for

anti-EBOV activity. For example, Compound 7
is a benzodiazepine derivative that also prevents

BCX4430, but no data in humans have been

EBOV

obtained to date. Currently, the timing of
treatment for drugs such as BCX4430 has not

Preliminary analysis suggests that Compound
7 binds near a hydrophobic pocket near the

been established, although early treatment in
high-risk
or
potentially
EBOV-exposed

EBOV GP1 and GP2 interface. Analysis of this
compound suggests that it may have activity

individuals may be an option [96]. Oral

against several filoviruses including EBOV [101].

administration of BCX4430 may be feasible,
although the pharmacokinetic data suggest that

No animal or human trials have been reported
to date.

the intramuscular route may provide more
favorable therapeutic levels [95].

NSC 62914 is a small molecule, which has an
antioxidant property, and was found to inhibit

Brincidofovir (CMX001)

many viruses, including EBOV, Lassa virus,
Venezuelan equine encephalitis virus and Rift

Brincidofovir is a prodrug of cidofovir and a

Valley fever virus [102]. This compound, a

fairly

reactive oxygen species, has shown in vitro

recent

oral

nucleotide

analog

that

entry

into

the

host

cells

[101].
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activity against EBOV as well as some evidence

NPC1 can also disrupt the release of EBOV from

in the EBOV mouse model for protection

the

against lethal EBOV infection at a treatment
dose of 2 mg/kg/injection (higher doses did not

Benzylpiperazine adamantane diamides are
NPC1 inhibitors that have been found to

improve survival in the mouse model). Further
studies of this or related compounds in mouse

interfere with EBOV binding to NPC1 on the
host cells and subsequently inhibit EBOV entry

and other animal models may be warranted to

and

elucidate their role in the treatment of EBOV
and other filovirus infections.

toremifene, which are selective estrogen
receptor modulators, have recently been

Of additional interest are compounds that
have been proven to be effective in preventing

discovered to have NPC1 inhibitor activity and
act as potential inhibitors of EBOV [109, 110].

the entry of filoviruses, including EBOV, into

Some anti-arrhythmic therapeutics such as

host cells [103]. LJ-001 binds to lipid membranes
and prevents virus-cell fusion across a wide range

amiodarone and verapamil also have been
identified as potent NPC1 inhibitors of the

of viruses. Additional research will be needed to
understand how such compounds can be

entry of the EBOV [109, 111]. Their
effectiveness has been proven in cell culture,

optimally formulated to maximize both the

and some trial work on amiodarone is under

safety and pharmacologic activity in vivo.
FGI-103, FGI-104, and FGI-106 are a group of

preparation now in West Africa [112].

broad-spectrum antiviral agents that inhibit viral
replication in a dose-dependent manner among

Immunotherapy

multiple and genetically distinct viruses
including EBOV, bunyaviruses, dengue virus,

Convalescent Whole Blood and Plasma
Historically, convalescent whole blood (CWB)

HIV and hepatitis C virus [104]. Using a mouse

and plasma (sometimes referred to as
convalescent sera) and hyperimmune serum

model, Aman et al. found that FGI-106 yields a
protection after a challenge with a lethal dose of

intracellular

infection

vesicular

[108].

compartment.

Clomiphene

and

(HS) have been employed for diseases that

EBOV. Aman and colleagues showed that
protection was also found when FGI-106 was

may be severe or result in serious
consequences and for which there is no safe

administered in a prophylactic fashion. In

and effective drug or vaccine. In 1995, passive
immunotherapy or convalescent immune

related studies, FGI-103 and FGI-104 are also
small molecules that inhibit filovirus infection
and are found
Marburg-infected

to protect EBOV- or
mice,
although
their

mechanism of actions are unclear [105, 106].
In 2011, a novel finding by Carette et al.
showed that EBOV cell entry requires the endo/

plasma was used clinically to treat patients
with EVD in the outbreak of Kikwit, DRC
[113]. In this study, eight patients were given
the blood of convalescent patients where 7/8
(87.5%) of patients survived the disease. To
date, however, there are no definitive human

lysosomal
Niemann-Pick
C1
cholesterol
transporter protein (NPC1) [107]. NPC1 is a

clinical trial data showing that CWB or CP are
effective in reducing either the severity or

fundamental component to facilitate EBOV

duration of EVD [114]. In animal studies
reported in 2007, Jahrling et al. used whole

glycoprotein host membrane fusion. Cells that
are defective in the NPC1 are resistant to
infection by EBOV. In addition, inhibition of

blood

from

surviving

non-human

EVOV

infection

primates
to

treat

(NHPs)
other
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animals, which challenged with lethal dose of

treating a Spanish nurse who had contracted

EBOV

study

EBOV during her care to a patient with EVD in

concluded that there was no beneficial effect
following
the
administration
of

Spain shed some light on the issue of using
experimental therapeutics including CP [121].

convalescent-phase
EBOV-infected NHPs.

[115].

Researchers

in

this

blood

to

The infected nurse had received convalescent
sera from two survivors of EVD, high-dose

colleagues

used

favipiravir and other supportive care treatment.

multiple doses of concentrated polyclonal IgG
antibody from NHPs that had survived filovirus

On the 10th day of clinical disease, the nurse
developed clinical signs and symptoms

infection to treat Marburg virus-infected NHPs
[116]. Results of this study demonstrated very

suggestive of post-transfusion acute lung injury,
which was managed conservatively without the

effective post-exposure IgG treatment where

need of supportive mechanical ventilation.

none of the experimental NHPs showed signs
of the disease or detectable viremia.

Although purified IgG can lower these risks,
lot-to-lot variation remains a potential problem.

Furthermore,
surviving
NHPs
were
re-challenged with Marburg virus, and all

Previous experience also highlights the risk of
antibody-dependent enhancement of EBOV

survived the re-challenge, indicating that they

infection [122]. To address challenges with

were able to produce Marburg virus-specific IgM
antibodies to fight virus replication. Subsequent

convalescent sera-based therapies, researchers
have developed highly purified polyclonal

evaluations were conducted to demonstrate
Marburg virus or EBOV-infected NHPs could

antibodies or monoclonal antibodies that
specifically target neutralizing glycoprotein

survive the disease even if IgG treatment was
delayed 2 days post infection. Successfully, both

epitopes of the EBOV envelope [123]. The
long-term prospects for use of CP also require

Marburg- and EBOV-infected animals survived

clinical

the disease, though one out of three infected
animals showed mild disease yet fully recovered

collection and testing of CWB or CP from
recovered Ebola patients in order to ensure

afterwards. Promising results of these studies
demonstrate the effectiveness of post-exposure

administration of safe blood products in the
context of an EVD outbreak.

In

contrast,

Dye

whole
and

laboratory

infrastructure

for

the

antibody treatments and represent an option
for EVD therapies for human use.
In the current West Africa Ebola outbreak,

Monoclonal Antibodies (ZMapp)
Natural infection with EBOV induces antibodies

convalescent-phase plasma administration for
treatment of EVD is undergoing an open label,

directed
against
the
EBOV
envelope
transmembrane
glycoprotein,
which
is

phase II/III nonrandomized trial among 130–200

essential to virus attachment, fusion and entry

patients in Guinea [117]. For use of CP or CWB,
the WHO has provided guidance to improve the

into host cells. In the past several years, a
number of studies have developed and

safety of product development as well as safety
for patients who receive these products

characterized monoclonal antibodies directed
against epitopes of EBOV antigens. Within the

[118–120]. Convalescent sera-based therapy

genus Ebolavirus, there are five antigenically
distinct viruses that generate antibodies that

may cause some toxicity related problems, such
as transmission of undetected pathogen(s) and
transfusion reactions. A recent case report from

may or may not cross-react with other Ebola
species. In 2015, Hernandez and colleagues used
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a panel of mouse monoclonal antibodies to

rhesus macaques when MB-003 monoclonal

extensively study cross-reactivity, avidity and

antibodies were first administered at 48 h

viral GP epitope binding [124]. This research
team identified four monoclonal cross-reactive

post-exposure followed by two additional
doses [125]. In this study, MB-003 monoclonal

antibodies that bind to GPs of five Ebolavirus
species. These findings suggest that monoclonal

antibodies protected four of six animals (67%)
against EBOV infection.

antibodies directed against the five species of

In an effort to optimize the monoclonal

Ebolavirus may be useful for both clinical
diagnosis and therapy.

antibody cocktail composition to contain the
most
potent
epitopes
for
neutralizing

In earlier efforts, investigators developed a
cocktail of antibodies from two groupings

antibodies that may effectively inhibit EBOV
replication
and
further
prolong
the

(MB-003 and ZMab), each containing three

post-exposure treatment window, a group of

unique monoclonal antibodies. MB-003 was
composed of three humanized chimeric

researchers conducted an animal study to test
different
combinations
of
monoclonal

monoclonal antibodies (c13C6, c6D8 and
h13F6) [123], while ZMAb was composed of

antibodies from MB-003 and ZMAb [132].
After several animal experimental trials,

three other different monoclonal antibodies

investigators of this study selected ZMapp as

(m1H3, m2G4 and m4G7) [125]. By direct and
specific reaction with EBOV GP, these

the best monoclonal antibody formulation with
the best protection effect. ZMapp was composed

antibodies are thought to provide passive
immunity against the virus by directly reacting

of one monoclonal antibody from MB-003
(c13C6) and two monoclonal antibodies from

with the EBOV envelope glycoprotein
[126–128]. In one study, ZMAb demonstrated

ZMAb (2G4 and 4G7). With this selected
combination of monoclonal antibodies, rhesus

100% efficacy in NHPs where four of four

macaques were treated with ZMapp at 5, 8 and

cynomolgus
macaques
survived
EBOV
infection when given the first dose of ZMAb

11 days after challenge with EBOV at a lethal
dose of 50 mg/kg per dose. Although animals of

24-h after exposure followed by two additional
doses 3 days apart. However, when the first dose

this study exhibited signs and symptoms of EVD
and viral load was detected at 5 days

was delayed and given at 48 h after a lethal dose

post-challenge before treatment with ZMapp

of EBOV exposure, 50% of the monkeys fully
recovered [129]. A potent humoral and

was initiated, all animals survived. A follow-up
at 3 weeks post EBOV-exposure demonstrated

cell-mediated immune response was mounted
in all animals recovered from the lethal

an undetectable viral load in all animals [132].
This is strong evidence that ZMapp could be

challenge of EBOV, and all survived monkeys

a potential therapeutic modality in humans

fully recovered from a subsequent EBOV
reintroduction [130]. Recent research showed

even when signs and symptoms of EVD have
manifested. In July 2014, two US healthcare

that treatment with ZMAb can be delayed as
late as 72 h post EBOV exposure when ZMAb is

workers were brought from Liberia to the USA
after being diagnosed with EVD and were

given in combination with adenovirus vectored

treated with aggressive fluid replacement and

human interferon-a [131]. In 2012, another
group of researchers demonstrated a high

electrolyte correction. Both were given ZMapp
and showed a decline in the level of Ebola

protection rate against EBOV infection among

plasma viral load in correlation with clinical
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improvement. Although they improved shortly

symptoms of EVD with direct antiviral action.

after receiving ZMapp, their clinical course

Despite the high safety profile compared with

cannot be exclusively attributed to the
monoclonal antibodies, as other measures of

other newly discovered antivirals, these agents
cannot be used alone because of their low

care could have and probably did play a major
role to the clinical improvement [133].

efficacy, but they can be used in combination
with other treatments available including

Clinical use of ZMapp maybe practically

supportive care measures.

challenging given the limited supplies of the
drug since the three monoclonal antibodies of

Interferon: Since its discovery in 1950,
interferon has not been widely used because of

ZMapp are currently extracted from the plant
Nicotiana benthamiana [132]. A new scalable

the associated adverse events [123]. The
potential use of interferons in the treatment of

transient expression technology (magnifection)

EVD is rooted in the evidence that EBOV

could overcome future ZMapp shortages. Using
magnifection, 0.5 g of ZMapp can be extracted

interferes with functions of type I interferons
[137–139]. Previous pre-clinical research

and purified from 1 kg N. benthamiana leaf
biomass [134]. While this product holds

showed that exogenous interferon-a or
interferon-b could delay the occurrence of

promise, a major hurdle in its future utility is to

viremia or prolong survival time, but could

manufacture large quantities of each monoclonal
antibody from plants in a way that ensures

not save animals from death [140, 141].
Recombinant
Nematode
Anticoagulant

sustained high yield of monoclonal antibodies
at reasonable cost [135]. To overcome potential

Protein c2 (rNAPc2) and Recombinant Human
Activated Protein c (rhAPC): EBOV infections

rate-limiting steps in large-scale production,
ZMapp can be manufactured using Chinese

cause coagulation diathesis as one of the
important pathogenesis factors for the

hamster ovary (CHO) cells.

development of EVD [142]. The two originally

In February 2015, a partnership between
Liberia and the US National Institute of

licensed anticoagulant
rNAPc2 and rhAPC.

Allergy and Infectious Diseases (NIAID)
initiated clinical trials to evaluate the safety

demonstrated in previous studies partial
protection of NHPs from ZEBOV lethal

and efficacy of ZMapp in the treatment of EVD.

challenge, with associated survival rates of

The original study is designed to have two-arm
comparison with each arm including 100

33% and 18%, respectively [143, 144]. In
December 2014, the US FDA granted the

people; one arm will receive the standard of
care and the other arm the experimental ZMapp

manufacturer (ARCA Biopharma, Westminster,
CO) orphan drug status for rNAPc2 as a

treatment [136]. While randomized controlled

potential post-exposure treatment for EVD

trials are planned, with declining EVD case
loads, a modification of the original trial

[145].

designs may be required to evaluate the safety
and efficacy of ZMapp.

Ebola Vaccine Candidates

drugs available are
These drugs have

Nonspecific Agents

Ebola vaccine development was initiated in
the 1980s. A number of vaccine candidates

Many potential therapeutic agents have shown

have been tested in rodents and

some

including inactivated virus, DNA vaccines,

post-exposure efficacy in

alleviating

NHPs,
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virus-like particles (VLPs) and vaccines based

adenoviruses and vesicular stomatitis virus

on recombinant viral vectors [146]. Animal

modified to express the EVOB surface GP.

models have been developed to test the
efficacy of vaccine candidates, including
mice, guinea pigs and other NHPs. Rodent
models do not always predict vaccine efficacy

FUTURE DIRECTIONS

in NHPs and employ EBOV-adapted strains.

Evidence identified through the cumulative
experience across multiple EVD outbreaks

NHPs (usually rhesus and cynomolgus
macaque) can be infected with non-adapted

since the 1970s strongly suggests that EVD
can be considered a zoonotic disease that has

strains and best mimic disease progression in
humans, and therefore they are considered the

emerged and spread as human contact with

‘‘reference’’ animal model for vaccine studies

wild animal species has increased. Additional
ecological, epidemiologic and clinical disease

[147]. Differences can also be found in the
EBOV antigens included in the vaccines.

surveillance will continue to be important
throughout Ebola-endemic countries and to

While the main antigen for vaccine
development has been the EBOV surface GP,

investigate

possible

triggering

factors

and

VLPs-based

predictors of new future outbreaks. In 2014
and 2015, the rapid evolution of the West

vaccine have also included the NP and the
VP40 matrix protein. A novel approach

Africa outbreak highlighted the need for
additional
research
into
systems
and

includes a replication-deficient recombinant
EBOV lacking the gene encoding for VP30,

technologies that accelerate local, national

some

candidates

such

as

the

an essential transcription factor that plays a
fundamental role in viral replication [148],
and has been recently shown to protect NHPs
against EBOV [149]. This vaccine differs from
other EBOV advanced vaccine platforms in
that all viral proteins and the viral RNA are
presented to the immune system, which
might

contribute

to

protective

immune

responses.
With the global impact of the West Africa
EVD outbreak, research and development for
new Ebola vaccine candidates has been
stimulated, though no licensed vaccine is
currently available. In the past year,
investment in vaccine candidates has led to
initiation of phase I, II and III human clinical
trials (Table 2). More advanced vaccine
candidates are based on viral vectors such as

and
international
health
organization
responsiveness to containment of EBOV
transmission and epidemics. Multi-disciplinary
team-based research will be extremely
important particularly given the socio-cultural
factors that have fueled and sustained EVD
outbreaks. While new diagnostic tests look
promising in providing more timely and
accurate EBOV detection, there will be a need
for

additional

research

to

study

optimal

strategies for deploying these diagnostics to
locations where testing is most needed. In the
near future, there is a substantial likelihood
that one or more drugs and vaccines will be
approved

for

use

in

the

treatment

and

prevention of EVD. The availability of new
agents for prevention, acute therapy and
post-exposure
prophylaxis
will
require
additional research to identify and reduce

US

University of Maryland
NIAID

(Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)

VRC-EBOADC069-00-VP (cAd3-EBO), Ebola Chimpanzee
Adenovirus Vector Vaccine

Uganda

NIAID

VRC-EBOADC069-00-VP (cAd3-EBO) (Ebola Chimpanzee
Adenovirus Vector Vaccine)

VRC-EBOADC076-00-VP (cAd3-EBOZ), Ebola Chimpanzee
Adenovirus Vector Vaccines

US

NIAID

Mali

VRC-EBOMVA079-00-VP (MVA-EbolaZ) (Ebola Modiﬁed
Vaccinia Virus Ankara Vaccine) with and without boost to
VRC-EBOADC069-00-VP (cAd3-EBO)

VRC-EBOADC076-00-VP (cAd3-EBOZ), Ebola Chimpanzee
Adenovirus Vector Vaccines

Mali

University of Maryland with Wellcome
Trust,
NIAID and Leidos, Inc.

cAd3-EBOZ with MVA-BNÒ FILO (Prime-Boost regimen)

Sierra
Leone

US Centers for Disease Control and
Prevention (CDC)

rVSVDG-ZEBOV (recombinant vesicular stomatitis virus
expressing the envelope glycoprotein of Ebola virus Zaire)

China

Jiangsu Province CDC with Beijing
Institute of Biotechnology and Tianjin
Cansino Biotechnology, Inc.

Ad5-EBOV (Ebola Adenovirus Vector Vaccine)

VRC-MARDNA025-00-VP [158] (Marburg DNA Plasmid
Vaccine)

NCT02326194

Phase IB
ongoing

Phase I/IB
ongoing

Phase I
ongoing

Phase I
ongoing

Phase IB
ongoing

NCT02354404

NCT02408913

NCT02231866

NCT02368119

NCT02267109

Phase II/III NCT02378753
ongoing

Phase I
ongoing

Phase I
NCT00605514
completed

US

NIAID

VRC-EBODNA023-00-VP [158] (Ebola DNA Plasmid Vaccine)

VRC-MARDNA025-00-VP [157] (Marburg DNA Plasmid
Vaccine)

Phase IB
NCT00997607
completed

ClinicalTrials.gov
identiﬁer number

National Institute of Allergy and Infectious Uganda
Diseases (NIAID)

Stage of
evaluation

VRC-EBODNA023-00-VP [157] (Ebola DNA Plasmid Vaccine)

Location

Sponsor or manufacturer

Vaccine candidate names

Table 2 Overview of EVD developing vaccines
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UK
UK
Australia

University of Oxford
University of Oxford
Novavax
NIAID
NIAID
University of Oxford, WHO, Wellcome
Trust and others
First Afﬁliated Hospital of Zhejiang
University,
Beijing Institute of Bioengineering,
Academy
of Military Medical Sciences, Tianjin
Cansino Biotechnology Inc.

Monovalent Zaire Ebola Viral Vector Candidate Vaccine
(cAd3-EBO Z) with MVA-BNÒ Filo (Prime-boost regimen)

MVA-EBO Z alone and cAd3-EBO Z with MVA-EBOZ
(prime-boost regimen)

EBOV GP Vaccine (Ebola Virus Glycoprotein) with or without
Matrix-MÒ adjuvant

VRC-EBOADV018-00-VP (Recombinant Ebola Adenoviral
Vector Vaccine)

VSVG-ZEBOV (Vesicular stomatitis virus-Ebola Zaire) and
ChAd3-EBO Z (chimpanzee adenovirus 3-Ebola Zaire)

VSV-ZEBOV

Ad5-EBOV (Adenovirus type 5 vector-based EBOV)

BPSC-1001 (VSV DG-ZEBOV) (recombinant vesicular stomatitis NewLink Genetics Corp.
virus expressing envelope glycoprotein of Ebola virus Zaire

Canada

Dalhousie University, Canadian Institutes
of Health Research, NewLink Genetics
Corp.

rVSVD-ZEBOV GP (BPSC1001)

US

China

Kenya

Liberia

US

Germany

Universitätsklinikum Hamburg-Eppendorf

rVSVD-ZEBOV GP (BPSC1001)

Location

Sponsor or manufacturer

Vaccine candidate names

Table 2 continued

NCT02370589

NCT02451891

NCT02240875

NCT02374385

NCT02283099

ClinicalTrials.gov
identiﬁer number

Phase I
ongoing

Phase I
ongoing

Phase I
ongoing

Phase II
ongoing

NCT02314923,
NCT02269423,
NCT02280408a

NCT02401373

NCT02296983

NCT02344407

Phase I
NCT00374309
completed

Phase I
ongoing

Phase I
ongoing

Phase IA
ongoing

Phase I
ongoing

Phase I
ongoing

Stage of
evaluation
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Sponsor or manufacturer

University of Lausanne Hospitals
NIAID
Regional Center of Excellence and by
Health
and Labour Sciences Research Grants,
Japan

cAd3-EBOZ (Monovalent Zaire Ebola Chimpanzee Adenovirus
Vector Candidate Vaccine)

VRC-EBODNA012-00-VP (Multiple Strain Ebola DNA Plasmid
Vaccine)

EBOVDVP30 (EBOV) vaccine based on a replication-defective
EBOV

a

University Hospital, Geneva, WHO,
Wellcome
Trust and others

BPSC-1001 (VSV G-ZEBOV)

Trial evaluating BPSC-1001 (VSV DG-ZEBOV in a prime-boost regimen)

NIAID

Crucell Holland BV

MVA-BN-Filo and Ad26.ZEBOV

MVA-BN-Filo and Ad26.ZEBOV (human adenovirus serotype 26 Crucell Holland BV
expressing the Ebola virus Mayinga variant glycoprotein)

Vaccine candidate names

Table 2 continued

Japan and
US

US

NCT02289027

Animal
[149]
study
completed

Phase I
NCT00072605
completed

Switzerland Phase I/II
ongoing

NCT02287480

Switzerland Phase I/II
ongoing

NCT02313077,
NCT02376426,
NCT02376400,
NCT02325050

Phase I
ongoing

NCT02416453

ClinicalTrials.gov
identiﬁer number

Stage of
evaluation

Phase II
ongoing

UK

US

Tanzania/
Uganda

Ghana/
Kenya

UK

Location
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2.

Centers for Disease Control and Prevention.
Ebola
(Ebola
virus
disease),
outbreaks
chronology: Ebola virus disease. 2015. http://www.
cdc.gov/vhf/ebola/outbreaks/history/chronology.
html. Accessed 07 May 2015.
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